Although Not Improving DFS, Adjuvant Avelumab May Potentially Reduce the Risk of Death in Patients with High-Risk TNBC By Ogkologos - September 9, 2025 581 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the A-BRAVE study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Rise in Brain Metastases Detected in Patients with Stage IV NSCLC... March 24, 2021 EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin and Pembrolizumab September 3, 2024 A Favourable Benefit-Risk Profile for Taletrectinib in TKI-Naїve and Crizotinib-Pretreated Patients... July 24, 2024 Patient-Reported Outcomes Support the Overall Benefit of Trastuzumab Deruxtecan for Patients... May 24, 2023 Load more HOT NEWS Age and Frailty Should Be Considered Independently When Evaluating Potential Risk... Withdrawal of the Application to Change the EMA Marketing Authorisation for... ΣΤΑΤΙΣΤΙΚΑ What Is Intuitive Eating and How Can It Help During Cancer?
